Total Payments
$126,573
2024 Payments
$281.47
Companies
27
Transactions
207
Medicare Patients
2,823
Medicare Billing
$193,550
Payment Breakdown by Category
Research$66,248 (52.3%)
Other$42,627 (33.7%)
Travel$11,502 (9.1%)
Food & Beverage$5,101 (4.0%)
Consulting$900.00 (0.7%)
Education$194.98 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $66,248 | 28 | 52.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,377 | 7 | 23.2% |
| Honoraria | $13,250 | 4 | 10.5% |
| Travel and Lodging | $11,502 | 31 | 9.1% |
| Food and Beverage | $5,101 | 133 | 4.0% |
| Consulting Fee | $900.00 | 2 | 0.7% |
| Education | $194.98 | 2 | 0.2% |
Payments by Type
Research
$66,248
28 transactions
General
$60,326
179 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $66,663 | 23 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $36,682 | 34 | $0 (2024) |
| VYNE Pharmaceuticals Inc. | $15,105 | 19 | $0 (2021) |
| PFIZER INC. | $4,208 | 22 | $0 (2023) |
| Endo Pharmaceuticals Inc. | $1,799 | 11 | $0 (2018) |
| ABBVIE INC. | $518.99 | 23 | $0 (2022) |
| Janssen Biotech, Inc. | $214.30 | 9 | $0 (2023) |
| Amgen Inc. | $196.21 | 8 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $193.11 | 6 | $0 (2023) |
| Lilly USA, LLC | $153.02 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $281.47 | 12 | E.R. Squibb & Sons, L.L.C. ($74.92) |
| 2023 | $37,147 | 52 | E.R. Squibb & Sons, L.L.C. ($36,559) |
| 2022 | $297.49 | 14 | ABBVIE INC. ($44.25) |
| 2021 | $7,387 | 11 | VYNE Pharmaceuticals Inc. ($7,355) |
| 2020 | $10,577 | 16 | VYNE Pharmaceuticals Inc. ($7,750) |
| 2019 | $21,130 | 39 | Eli Lilly and Company ($16,603) |
| 2018 | $47,137 | 34 | Eli Lilly and Company ($45,041) |
| 2017 | $2,617 | 29 | Eli Lilly and Company ($2,214) |
All Payment Transactions
207 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Immunology | ||||||
| 10/11/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $28.73 | General |
| Category: Immunology | ||||||
| 08/22/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $19.70 | General |
| Category: Immunology | ||||||
| 08/06/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Dermatology | ||||||
| 06/06/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Genetic Disease | ||||||
| 04/23/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Immunology | ||||||
| 04/09/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: DERMATOLOGY | ||||||
| 03/28/2024 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Immunology | ||||||
| 03/26/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $38.39 | General |
| Category: Immunology | ||||||
| 03/12/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Inflammation | ||||||
| 02/06/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $16.83 | General |
| Category: Immunology | ||||||
| 01/22/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.67 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/17/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,756.00 | General |
| Category: Immunology | ||||||
| 11/14/2023 | Sun Pharmaceutical Industries Inc. | Winlevi (Drug), Absorica LD | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Dermatology | ||||||
| 11/07/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: DERMATOLOGY | ||||||
| 11/03/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $12.77 | General |
| Category: Dermatology | ||||||
| 09/26/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $26.05 | General |
| Category: Dermatology | ||||||
| 09/15/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: DERMATOLOGY | ||||||
| 09/12/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,756.00 | General |
| Category: Immunology | ||||||
| 08/22/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $8.80 | General |
| Category: Immunology | ||||||
| 08/15/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $14.00 | General |
| 08/01/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Dermatology | ||||||
| 07/18/2023 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Immunology | ||||||
| 07/10/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $94.99 | General |
| Category: Immunology | ||||||
| 06/26/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $38,145 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $8,710 | 2 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $6,188 | 2 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $5,880 | 3 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $2,477 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | Endo Pharmaceuticals Inc. | $1,799 | 11 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $1,190 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $1,099 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $399.95 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | Eli Lilly and Company | $294.16 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $65.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 784 | 1,706 | $165,913 | $59,136 |
| 2022 | 13 | 620 | 1,057 | $110,974 | $36,649 |
| 2021 | 12 | 1,024 | 1,695 | $171,689 | $72,509 |
| 2020 | 11 | 395 | 729 | $74,156 | $25,257 |
Total Patients
2,823
Total Services
5,187
Medicare Billing
$193,550
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 137 | 223 | $33,486 | $12,176 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 92 | $19,403 | $7,949 | 41.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 129 | 129 | $23,687 | $7,257 | 30.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 62 | 92 | $17,066 | $6,454 | 37.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 121 | 191 | $21,206 | $6,353 | 30.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 85 | 102 | $16,885 | $6,156 | 36.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $13,011 | $4,247 | 32.6% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 17 | 17 | $8,434 | $3,500 | 41.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 90 | 701 | $7,759 | $3,223 | 41.5% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 18 | 18 | $3,654 | $1,250 | 34.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 13 | 14 | $1,170 | $510.01 | 43.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 80 | $152.00 | $60.66 | 39.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 125 | 125 | $24,154 | $7,538 | 31.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 62 | 73 | $13,903 | $4,587 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 78 | 93 | $12,749 | $4,359 | 34.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 74 | 77 | $13,261 | $4,020 | 30.3% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 16 | 17 | $9,038 | $3,433 | 38.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 85 | 107 | $12,243 | $3,152 | 25.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $9,546 | $3,003 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 32 | $6,697 | $2,560 | 38.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 69 | 370 | $4,106 | $1,809 | 44.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 19 | 27 | $2,395 | $1,011 | 42.2% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 11 | 11 | $2,396 | $982.02 | 41.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 11 | $324.00 | $123.31 | 38.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 13 | 81 | $162.00 | $71.22 | 44.0% |
About Dr. Ryan Harris, MD
Dr. Ryan Harris, MD is a Dermatology healthcare provider based in Meridian, Idaho. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2010. The National Provider Identifier (NPI) number assigned to this provider is 1952628745.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Harris, MD has received a total of $126,573 in payments from pharmaceutical and medical device companies, with $281.47 received in 2024. These payments were reported across 207 transactions from 27 companies. The most common payment nature is "" ($66,248).
As a Medicare-enrolled provider, Harris has provided services to 2,823 Medicare beneficiaries, totaling 5,187 services with total Medicare billing of $193,550. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Meridian, ID
- Active Since 05/03/2010
- Last Updated 02/22/2023
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1952628745
Products in Payments
- Sotyktu (Drug) $35,734
- AMZEEQ (Drug) $15,052
- EUCRISA (Drug) $1,322
- Humira (Biological) $422.46
- TREMFYA (Drug) $176.86
- Otezla (Drug) $128.69
- TALTZ (Drug) $116.21
- Enbrel (Biological) $93.72
- XEOMIN (Biological) $91.14
- DUPIXENT DUPILUMAB INJECTION (Biological) $61.39
- COSENTYX (Biological) $60.25
- ENSTILAR (Drug) $58.66
- ILUMYA (Biological) $55.46
- OPZELURA (Drug) $54.82
- ZILXI (Drug) $53.00
- VTAMA (Drug) $52.70
- COSENTYX (Drug) $46.00
- DUPIXENT (Drug) $43.12
- ELZONRIS (Drug) $36.80
- DUPIXENT (Biological) $36.67
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Meridian
Mark Schwendiman, D.o, D.O
Dermatology — Payments: $8,785
Dermatology $8,785
Dr. Kenneth Saul, M.d, M.D
Dermatology — Payments: $7,603
Dermatology $7,603
Kelsey Ferrell, Do, DO
Dermatology — Payments: $6,951
Dermatology $6,951
Dr. Randall Burr, M.d, M.D
Dermatology — Payments: $6,784
Dermatology $6,784
Benjamin Perry, D.o, D.O
Dermatology — Payments: $4,240
Dermatology $4,240
Anna Wile, M.d, M.D
Dermatology — Payments: $4,193
Dermatology $4,193